EDITORIAL: No debate needed on drug prices
Even President
The numbers are staggering: a more than 5,000 percent price increase for one medicine to treat parasitic infection, 2,000 percent for a drug to combat drug-resistant tuberculosis, 1,900 percent for a remedy for kidney and bladder stones.
These are not cases of companies investing millions to research and develop new drugs. The companies in question spent exactly zero on R&D.
Those price jumps came after the drugs were purchased from the companies that developed them by other companies, which then jacked up the price to recoup their investment and make enormous profits.
A bipartisan report by the
There is no question that developing new drugs is very expensive -- a function of the government's insistence on safety before releasing new drugs to the market. But when the companies that go to that expense are then bought out by other companies that boost the price even higher, it's the patients who lose -- and the insurance industry is forced to raise premiums and limit the patients who can receive the drugs to those who are sickest.
Patients and their families are willing to spend everything they own and more to obtain life-saving treatment. The drug companies know this, and price their products accordingly.
Solutions don't break down along party lines --
One obvious step is to allow
Another fix must involve caps on prices of the most expensive drugs, with manufacturers required to reveal more of their costs if they want to justify continuing to charge super-premium prices.
Speeding up the approval process for generic drugs also will help.
While lawmakers dither over how to address this crisis, the losers are the American people.
___
(c)2017 the Mail Tribune (Medford, Ore.)
Visit the Mail Tribune (Medford, Ore.) at www.mailtribune.com
Distributed by Tribune Content Agency, LLC.


Ex-jail nurse asks for more time to prepare for trial in inmate death case
Democrats to rally for Affordable Care Act this Saturday in Aiken
Advisor News
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
- Semi-retirement: helping clients balance flexibility with financial security
More Advisor NewsAnnuity News
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
- Jackson Launches Direct-to-Consumer Annuity Offering
- Global Atlantic launches ForeIncome Flex
- Athene CEO criticizes offshore reinsurance, risk-taking by competitors
- DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
More Annuity NewsHealth/Employee Benefits News
- Medicaid work rules don’t apply to Native Americans. They could still lose coverage.
- Oscar Highlights Tailored New Health Products in Florida for 2027 Open Enrollment
- Oscar Highlights Tailored New Health Products in Texas for 2027 Open Enrollment
- States get until July to cut Medicaid coverage over work requirement
- CRUSH Rule could crush health insurance agents, industry group says
More Health/Employee Benefits NewsLife Insurance News
- Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
- Military Briefs: November 19-25
- California’s new solvency rules: What should life insurance advisors watch?
- Navigating delayed death certificates: A guide for life insurance advisors
- Jackson Launches Direct-to-Consumer Annuity Offering
More Life Insurance News